Interleukin 2 as a potential cancer marker in patients after kidney transplantation

• Published in: Annals of Agricultural and Environmental Medicine 2015-01, Vol.22 (2), p.320-324
• Main Authors: Witkowska, Agnieszka, Zywiec, Joanna, Strozik, Agnieszka, Gorczynska-Kosiorz, Sylwia, Trautsolt, Wanda, Strzalka-Mrozik, Barbara, Kimsa, Magdalena, Owczarek, Aleksander, Stępień, Beata, Mazurek, Urszula, Grzeszczak, Władysław, Gumprecht, Janusz
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biomarkers - blood; Blood cells; Cancer; cancer marker; Enzyme-linked immunosorbent assay; Female; Follow-Up Studies; Humans; IL-1β; Immunosuppressive agents; Interleukin 1; Interleukin 10; Interleukin 2; Interleukin-10 - genetics; Interleukin-10 - metabolism; Interleukin-1beta - genetics; Interleukin-1beta - metabolism; Interleukin-2 - genetics; Interleukin-2 - metabolism; Kidney transplantation; Kidney Transplantation - adverse effects; Male; Malignancy; Middle Aged; mRNA; Neoplasms - immunology; Neoplasms - metabolism; Patients; Poland; Probes; Risk factors; Transplant Recipients; Transplants & implants; Tumor Necrosis Factor-alpha - genetics; Tumor Necrosis Factor-alpha - metabolism; Tumors
• ISSN: 1232-1966; 1898-2263
• DOI: 10.5604/12321966.1152087

Transplant recipients have a significantly greater incidence of cancer, compared with the general population, who are referred to immunosuppressive therapy as an additional malignancy risk factor. Therefore, there is a need to search for an easy in clinical practice neoplasm predictor, especially for this group of patients. A group of 74 (43M and 31F; aged 46.8 ± 12 years) kidney transplant recipients was investigated in a three-year follow-up study. During the time of observation, 7 patients were diagnosed with neoplasm (7.4 ± 1.5 years after transplantation). A serum level of IL2 (ELISA test) and mRNA level of IL1beta, IL10 and TNFalfa in peripheral mononuclear blood cells - PBMCs (QRT - PCR method) were measured in every year of observation. Analysis of variances and t-Student test were used in groups mean comparison: N - patients developing malignant neoplasm group (24 probes); M - set of probes from patients with malignancies at the moment of diagnosis (11 probes); P - set of probes from patients before developing malignant neoplasm (10 probes); C - control group of healthy transplant recipients (31 probes). Among the analyzed agents, only serum IL2 level differed between the analyzed groups, with higher values in the M compared with the P group (p